Analyst Reco. Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 17:25:41 16/03/2026 GMT			5-day change	1st Jan Change
243.01 ^USD	+0.62%		+0.04%	+17.27%

12:37pm	Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer	CI
12:36pm	Nasus Pharma Ltd Announces Positive Top Line Data from Phase 2 Clinical Study of NS002	CI

Analyst Reco.

08:56am	Bernstein: Risk in Alcon's Implantables Business 'Manageable,' Already Priced In	MT
03-11	Citigroup Adjusts Price Target on Johnson & Johnson to $274 From $250, Maintains Buy Rating	MT
03-05	United Therapeutics Seen as Top Pick on Multiple Near-Term Catalysts, UBS Says	MT
03-05	JPMorgan Adjusts Price Target on Johnson & Johnson to $250 From $225, Maintains Neutral Rating	MT
02-19	Rothschild & Co Redburn Adjusts PT on Johnson & Johnson to $210 From $180, Maintains Neutral Rating	MT
02-03	Johnson & Johnson's Solid Financial Position to Mitigate Talc Litigation Risk, RBC Says	MT
02-03	RBC Raises Price Target on Johnson & Johnson to $255 From $240, Keeps Outperform Rating	MT
01-30	HSBC Adjusts Johnson & Johnson PT to $265 From $240, Maintains Buy Rating	MT
01-29	Daiwa Securities Adjusts Price Target on Johnson & Johnson to $237 From $203, Maintains Outperform Rating	MT
01-28	Morgan Stanley Upgrades Johnson & Johnson to Overweight From Equalweight, Adjusts PT to $262 From $200	MT
01-23	Argus Raises Price Target on Johnson & Johnson to $240 From $210	MT
01-23	Bernstein Adjusts Price Target on Johnson & Johnson to $225 From $208, Maintains Market Perform Rating	MT
01-23	Guggenheim Adjusts Price Target on Johnson & Johnson to $240 From $227, Maintains Buy Rating	MT
01-22	Johnson & Johnson Reports Modest Q4 Beat but Stock Seems Fairly Valued, Morgan Stanley Says	MT
01-22	Goldman Sachs Adjusts Price Target on Johnson & Johnson to $250 From $240, Maintains Buy Rating	MT
01-22	Leerink Partners Adjusts Price Target on Johnson & Johnson to $232 From $201, Maintains Market Perform Rating	MT
01-22	Raymond James Adjusts Price Target on Johnson & Johnson to $237 From $209, Maintains Outperform Rating	MT
01-22	Wolfe Research Adjusts Price Target on Johnson & Johnson to $260 From $240, Maintains Outperform Rating	MT
01-22	Scotiabank Adjusts Price Target on Johnson & Johnson to $265 From $230, Maintains Sector Outperform Rating	MT
01-22	Stifel Adjusts Price Target on Johnson & Johnson to $220 From $205, Maintains Hold Rating	MT
01-22	JPMorgan Adjusts Price Target on Johnson & Johnson to $225 From $205, Maintains Neutral Rating	MT
01-22	Citigroup Adjusts Price Target on Johnson & Johnson to $250 From $232, Maintains Buy Rating	MT
01-22	TD Cowen Adjusts Price Target on Johnson & Johnson to $250 From $222, Maintains Buy Rating	MT
01-22	Morgan Stanley Adjusts Price Target on Johnson & Johnson to $200 From $197, Maintains Equalweight Rating	MT
01-22	Wells Fargo Adjusts Price Target on Johnson & Johnson to $240 From $230, Maintains Overweight Rating	MT